1 |
quality-adjusted life-year
(3908 times)
|
Medicine (425 times)
|
ICER (842 times) ICERs (245 times) WTP (137 times)
|
1985 Parameter estimates for a QALY utility model.
|
2 |
quality-adjusted life expectancy
(11 times)
|
Health Services (3 times)
|
ICER (3 times) 3D-CRT (1 time) BMI (1 time)
|
1994 Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis.
|
3 |
cost-per-quality-adjusted life year
(9 times)
|
Health Services (2 times)
|
DALY (2 times) ICERs (2 times) NICE (2 times)
|
2008 The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
|
4 |
quality of life year
(8 times)
|
Gastroenterology (2 times)
|
ICER (3 times) ACS (1 time) CT (1 time)
|
2004 Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
|
5 |
quality-adjusted LY
(8 times)
|
Health Services (2 times)
|
LY (6 times) ICERs (2 times) mCRC (2 times)
|
2005 Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain.
|
6 |
Quality of Life Adjusted Years
(6 times)
|
Neurology (1 time)
|
ACCI (1 time) AF (1 time) BBF (1 time)
|
2000 The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis.
|
7 |
quality-adjusted year of life
(5 times)
|
Vascular Diseases (1 time)
|
AMI (1 time) CI (1 time) HPV (1 time)
|
2001 Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
|
8 |
quality of life
(4 times)
|
Acquired Immunodeficiency Syndrome (1 time)
|
BMT (1 time) BS (1 time) CT (1 time)
|
2007 Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
|
9 |
quality
(3 times)
|
Medicine (2 times)
|
ETV (1 time) GDP (1 time) HBV (1 time)
|
2015 [Clinical and economic benefits of the new antidiabetic drugs in the Czech Republic].
|
10 |
quality life year
(3 times)
|
Hospitals (1 time)
|
COVID-19 (1 time) ETV (1 time) LVD (1 time)
|
2009 Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil.
|
11 |
Quality Ajusted Life Year
(2 times)
|
Medicine (1 time)
|
ICER (2 times) LQT (1 time) PICANT (1 time)
|
2015 Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis.
|
12 |
quality of life impact
(2 times)
|
Communicable Diseases (1 time)
|
CER (1 time) LVAD (1 time)
|
1999 [Epidemiology and cost-effectiveness analysis of hepatitis A vaccination in Liuzhou City].
|
13 |
quality-adjusted survival
(2 times)
|
Neoplasms (1 time)
|
BCBM (1 time) CI (1 time) NHS (1 time)
|
2006 Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases.
|
14 |
quality-associated life year
(2 times)
|
Female Urogenital Diseases (1 time)
|
ASC (1 time) DS (1 time) ICER (1 time)
|
2013 The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
|
15 |
QoL-adjusted life year
(1 time)
|
Vascular Diseases (1 time)
|
QOL (1 time)
|
2011 Cost and cost-effectiveness of cardiac surgery in elderly patients.
|
16 |
Quality Adjusted Life Year calculations
(1 time)
|
Medicine (1 time)
|
TTO (1 time)
|
2012 Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.
|